WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Zelos Therapeutics, Inc. has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 (hPTH (1-34), teriparatide). ZT-034 is being developed to compete with Eli Lilly and Company’s Forteo (teriparatide [rDNA origin]) in its existing market of approximately $800M in annual sales in 2008 for the treatment of osteoporosis. With the recent completion of safety studies demonstrating no damaging effects on the nasal lining, Zelos Therapeutics also plans to advance a novel, non-injectable nasal spray formulation of ZT-034 into clinical studies later this year. This simple and convenient dosage form could expand the market for parathyroid hormone (PTH) analogs such as teriparatide to considerably more than $1 billion.
